(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
CAS:668270-12-0
Chemical Formula:C25H28N8O2
MW:472.54
Availability: R&D; Commercialization
⬤ CAS No.668270-12-0
⬤ Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| English Name | Linagliptin |
| CAS No. | 668270-12-0 |
| Chemical Formula | C25H28N8O2 |
| Molecular Weight | 472.54 |
| EINECS | 1308068-626-2 |
| Related Categories | Pharmaceutical intermediates, pharmaceutical raw materials, fine chemicals |
| Mol | 668270-12-0.mol |
| Melting point | 202 ºC |
| Boiling point | 661.2±65.0 °C (Predicted) |
| Density | 1.39 |
| Storage conditions | Refrigerator |
| Solubility | Soluble in chloroform (a small amount), DMSO (a small amount), methanol (a small amount) |
| Acidity coefficient (pKa) | 10.01±0.20 (Predicted) |
| Form | Solid |
| Color | White to orange |
| Side Effects | Hypoglycemia, gastrointestinal discomfort (nausea, vomiting, diarrhea), allergic reactions (skin rash, itching), joint pain |
| Precautions | Not for use in patients with type 1 diabetes or diabetic ketoacidosis. Use with caution in patients with severe liver or kidney disease. Safety in pregnant and lactating women is not established. |
| Drug Interactions | Potential interactions with other antidiabetic medications. Consult healthcare provider before use. |
| Contraindications | Hypersensitivity to linagliptin or any of its components. |
| Uses | Lilagliptin is a new type of highly effective and selective dipeptidyl peptide-4 (DPP-4) inhibitor for the treatment of type 2 diabetes. |
| Mechanism of Action | Lilagliptin is a DPP-IV inhibitor. DPP-IV is an incretin hormone that exists in many tissues bound to proteins, such as the kidney, liver, brush edge of the small intestinal membrane, pancreatic duct, lymphocytes, endothelial cells, etc. The enzyme can inactivate GLP-1 by hydrolyzing the second alanine at the N-terminus. Therefore, inhibiting the enzyme can increase the concentration of GLP-1, prompting pancreatic cells to produce insulin, while reducing the concentration of glucagon, thereby exerting an anti-diabetic effect. |
| Side Effects | The most common side effects of linagliptin include upper respiratory tract infection, nasal congestion or runny nose, sore throat, muscle pain, headache, etc., and its mechanism needs further study. |
| Biological Activity | Linagliptin (BI-1356) is a highly potent and selective DPP-4 inhibitor with an IC50 of 1nM. It is more than 10,000-fold more selective for DPP-4 than for other dipeptidyl peptidases such as DPP-2, DPP-8, and DPP9. Linagliptin activates glomerular autophagy in a type 2 diabetes model. DPP4 mediates ferroptosis in TP53-deficient CRC cells. |
Exceptional Product Quality
“We have been sourcing pharmaceuticals from Tianming Pharmaceutical for several years now, and their product quality has consistently exceeded our expectations. Each batch undergoes rigorous testing, ensuring we receive only the highest quality products. This reliability has significantly contributed to our trust and satisfaction with their services. Highly recommended!”
June 15, 2023
Outstanding Technical Guidance
“The technical guidance provided by Tianming Pharmaceutical’s team has been invaluable to our research and development projects. Their experts are knowledgeable, responsive, and always willing to assist with detailed explanations and support. Their guidance has enabled us to optimize our processes and achieve remarkable results. We couldn’t ask for a better partner.”
June 15, 2023
Superior Service Experience
“Our experience with Tianming Pharmaceutical has been nothing short of excellent. Their customer service team is exceptionally responsive and dedicated to meeting our needs. From initial consultation to after-sales support, they have provided seamless, professional service. Their commitment to customer satisfaction is truly commendable.”
June 15, 2023
Precise Product Specifications
“Tianming Pharmaceutical has impressed us with their adherence to precise product specifications. Each order is meticulously packaged and delivered exactly as requested, ensuring that we receive products that perfectly meet our requirements. Their attention to detail and commitment to accuracy have made them a trusted supplier for our business.”
June 15, 2023
This article breaks down the 4 most costly mistakes — including incomplete documentation and ignored scalability — with verified industry data and real cases.
End-to-end supply chain for anti-diabetic intermediates. Covering DPP-4, SGLT-2 inhibitors & GPR40 agonists. Stable, compliant, scalable.
Drawing from on-the-ground experience in China’s top pharma clusters, this guide cuts through the jargon to reveal when to partner for complex innovation and when to buy from the workhorses of mature production.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
